MeSH term
Frequency | Condition_Probility | Acute Disease | 3 | 0.0 |
Adult | 114 | 0.0 |
Comparative Study | 31 | 0.0 |
Humans | 250 | 0.0 |
Aged | 81 | 0.0 |
*Aging | 2 | 1.0 |
Cohort Studies | 2 | 0.0 |
Adolescent | 53 | 0.0 |
English Abstract | 18 | 0.0 |
Female | 124 | 0.0 |
Middle Aged | 101 | 0.0 |
Retrospective Studies | 7 | 0.0 |
Aged, 80 and over | 29 | 0.0 |
Antigens, CD/metabolism | 6 | 0.0 |
Biopsy | 6 | 0.0 |
Diagnosis, Differential | 19 | 0.0 |
Immunohistochemistry | 44 | 0.0 |
Male | 127 | 0.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
*Proteins | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 111 | 0.0 |
Animals | 17 | 0.0 |
Antigens, CD/biosynthesis | 3 | 0.0 |
Cells, Cultured | 15 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 23 | 0.0 |
Antigens, CD/*metabolism | 2 | 0.0 |
Biological Markers/analysis | 6 | 0.0 |
Case-Control Studies | 3 | 0.0 |
Child | 39 | 0.0 |
Flow Cytometry | 40 | 0.0 |
Immunophenotyping | 62 | 2.0 |
Killer Cells, Natural/cytology/*immunology | 3 | 10.0 |
Time Factors | 4 | 0.0 |
Child, Preschool | 21 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
Peru | 2 | 4.0 |
Cell Line | 2 | 0.0 |
*Cytotoxicity, Immunologic | 4 | 0.0 |
Antigens, CD56/analysis/*immunology | 2 | 66.0 |
Follow-Up Studies | 7 | 0.0 |
Treatment Outcome | 5 | 0.0 |
Antigens, CD/immunology | 6 | 1.0 |
Gene Rearrangement, T-Lymphocyte | 4 | 3.0 |
Killer Cells, Natural/*pathology | 3 | 10.0 |
Lymph Nodes/pathology | 3 | 1.0 |
Antigens, CD56/analysis | 5 | 7.0 |
Antigens, CD57/analysis | 19 | 44.0 |
Antigens, CD8/*analysis | 4 | 5.0 |
Leukemia, T-Cell/*pathology | 2 | 20.0 |
Antigens, CD57/*metabolism | 5 | 100.0 |
Killer Cells, Natural/metabolism/*pathology | 2 | 40.0 |
Neoplasm Staging | 3 | 0.0 |
Prognosis | 8 | 0.0 |
Cell Count | 3 | 0.0 |
Adenoma/metabolism/*pathology | 3 | 23.0 |
Immunoenzyme Techniques | 16 | 0.0 |
Kidney Neoplasms/metabolism/*pathology | 3 | 17.0 |
Nephroblastoma/metabolism/*pathology | 2 | 40.0 |
Tumor Markers, Biological/metabolism | 5 | 1.0 |
Antigens, CD57/metabolism | 2 | 20.0 |
Phenotype | 22 | 0.0 |
Antigens, CD/analysis | 38 | 2.0 |
Fatal Outcome | 5 | 0.0 |
Killer Cells, Natural/immunology/*pathology | 3 | 23.0 |
Antigens, CD44/analysis/genetics | 2 | 100.0 |
DNA Primers | 2 | 0.0 |
Tumor Cells, Cultured | 15 | 0.0 |
ADP-ribosyl Cyclase | 4 | 0.0 |
*Antigens, CD | 2 | 0.0 |
Antigens, CD57 | 17 | 25.0 |
Immune Tolerance | 3 | 1.0 |
Infant | 12 | 0.0 |
Viral Load | 2 | 0.0 |
Dendrites/ultrastructure | 2 | 22.0 |
Microscopy, Electron | 5 | 0.0 |
Neoplasm Proteins/analysis | 4 | 1.0 |
Schwann Cells/pathology | 3 | 23.0 |
Skin Neoplasms/chemistry/*pathology | 2 | 4.0 |
Soft Tissue Neoplasms/chemistry/*pathology | 2 | 14.0 |
Tumor Markers, Biological/analysis | 10 | 1.0 |
Epithelium/pathology | 3 | 2.0 |
Hyperplasia | 3 | 0.0 |
Lymphocyte Count | 18 | 2.0 |
Statistics, Nonparametric | 4 | 0.0 |
T-Lymphocytes/immunology | 6 | 0.0 |
Antigens, CD/blood | 4 | 1.0 |
Antigens, CD57/blood | 2 | 100.0 |
CD8-Positive T-Lymphocytes/*immunology | 5 | 1.0 |
Drug Therapy, Combination | 3 | 0.0 |
Kidney Transplantation/*immunology | 2 | 0.0 |
Longitudinal Studies | 2 | 0.0 |
Lymphocyte Activation | 20 | 0.0 |
T-Lymphocyte Subsets/*immunology | 22 | 4.0 |
Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 2 | 6.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Blotting, Western | 4 | 0.0 |
Cell Adhesion | 4 | 0.0 |
Cell Differentiation | 8 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Killer Cells, Natural/cytology | 2 | 8.0 |
Microscopy, Fluorescence | 3 | 0.0 |
Receptors, Interleukin-2/biosynthesis | 3 | 2.0 |
*Antibody Formation | 2 | 2.0 |
Infant, Newborn | 7 | 0.0 |
Biological Markers | 6 | 0.0 |
B-Lymphocytes/immunology | 2 | 0.0 |
Neck | 2 | 3.0 |
Liver Neoplasms/*pathology | 2 | 3.0 |
Receptors, Antigen, T-Cell, gamma-delta/analysis | 3 | 8.0 |
Leukemia, Lymphocytic/*pathology | 2 | 10.0 |
S100 Proteins/analysis | 6 | 3.0 |
Survival Analysis | 3 | 0.0 |
*Immunohistochemistry | 3 | 3.0 |
Sarcoma/pathology | 2 | 20.0 |
Antigens, CD57/*analysis | 5 | 55.0 |
B-Lymphocytes/*pathology | 3 | 6.0 |
T-Lymphocytes/*pathology | 3 | 4.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
Karyotyping | 7 | 0.0 |
Rosette Formation | 3 | 0.0 |
Translocation, Genetic | 3 | 0.0 |
*Immunophenotyping | 2 | 1.0 |
Reference Values | 7 | 0.0 |
Alkaline Phosphatase/analysis | 2 | 3.0 |
Antigens, CD34/analysis | 2 | 0.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 4 | 1.0 |
Phosphopyruvate Hydratase/analysis | 2 | 2.0 |
Vimentin/analysis | 2 | 0.0 |
Antigens, CD3/*analysis | 2 | 6.0 |
Cell Adhesion Molecules/*analysis | 3 | 2.0 |
Killer Cells, Natural/*immunology | 19 | 3.0 |
Antigens, Surface/analysis | 7 | 1.0 |
CA-15-3 Antigen/analysis | 3 | 4.0 |
Killer Cells, Natural/immunology | 11 | 2.0 |
Neprilysin/analysis | 2 | 3.0 |
Neural Cell Adhesion Molecules/analysis | 2 | 13.0 |
Antigens, CD56/immunology | 3 | 21.0 |
Antigens, CD57/*immunology | 2 | 33.0 |
Flow Cytometry/methods | 4 | 1.0 |
Mice | 7 | 0.0 |
Interleukin-2/pharmacology/therapeutic use | 2 | 40.0 |
Cytokines/blood | 2 | 0.0 |
Th1 Cells/*immunology | 2 | 1.0 |
Collagen/analysis | 2 | 2.0 |
*Translocation, Genetic | 2 | 0.0 |
Gene Rearrangement | 2 | 0.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Lung/*immunology | 2 | 4.0 |
Lymphocytes/*immunology | 3 | 0.0 |
Cytotoxicity, Immunologic | 13 | 1.0 |
Antibodies, Monoclonal/analysis | 2 | 2.0 |
Antigens, CD/*biosynthesis | 5 | 2.0 |
Cytomegalovirus/*immunology | 2 | 3.0 |
Immunologic Memory/*immunology | 2 | 6.0 |
Antigens, Differentiation/metabolism | 2 | 1.0 |
Disease-Free Survival | 2 | 0.0 |
Prevalence | 2 | 0.0 |
CD4-Positive T-Lymphocytes/immunology | 7 | 0.0 |
CD8-Positive T-Lymphocytes/immunology | 3 | 0.0 |
Cytomegalovirus Infections/complications/*immunology | 2 | 66.0 |
Severity of Illness Index | 2 | 0.0 |
Lymphatic Metastasis | 2 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
Antigens, CD45/analysis | 5 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis | 8 | 3.0 |
CD4 Lymphocyte Count | 2 | 0.0 |
Immunity, Cellular | 5 | 0.0 |
Lymphocyte Subsets | 7 | 3.0 |
Antigens, CD28/analysis | 2 | 5.0 |
Antigens, Differentiation/analysis | 6 | 1.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 2 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 6 | 1.0 |
CD4-CD8 Ratio | 7 | 1.0 |
CD4-Positive T-Lymphocytes/*immunology | 4 | 0.0 |
Cell Adhesion Molecules/analysis | 2 | 1.0 |
Histocompatibility Antigens Class II/analysis | 2 | 1.0 |
*Lymphocyte Activation | 2 | 0.0 |
Membrane Glycoproteins/analysis | 2 | 0.0 |
Receptors, IgG/analysis | 4 | 6.0 |
Sarcoidosis, Pulmonary/*immunology | 2 | 11.0 |
Lymphocyte Activation/immunology | 5 | 0.0 |
Prospective Studies | 3 | 0.0 |
*Membrane Glycoproteins | 3 | 0.0 |
Antigens, CD56/*immunology | 2 | 14.0 |
DNA, Neoplasm/analysis | 4 | 0.0 |
Leukocyte Count | 14 | 0.0 |
Lymphocyte Subsets/immunology | 6 | 4.0 |
Neutrophils/immunology | 2 | 1.0 |
Antigens, CD/*analysis | 14 | 1.0 |
Antigens, CD4/analysis | 4 | 0.0 |
Killer Cells, Natural/*pathology/ultrastructure | 2 | 100.0 |
Age Factors | 5 | 0.0 |
Antigens, CD28/*analysis | 2 | 10.0 |
Apoptosis | 3 | 0.0 |
Regression Analysis | 2 | 0.0 |
Cytokines/genetics | 2 | 1.0 |
Interferon Type II/biosynthesis | 2 | 0.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Receptors, Antigen, T-Cell, alpha-beta/*genetics | 2 | 2.0 |
Antigens, CD56/*analysis | 2 | 6.0 |
Fetal Blood/*cytology | 3 | 1.0 |
Interleukin-2/pharmacology | 2 | 0.0 |
Receptors, Antigen, T-Cell, gamma-delta/*analysis | 3 | 7.0 |
T-Lymphocyte Subsets/cytology/*immunology | 2 | 8.0 |
Cytokines/biosynthesis | 5 | 0.0 |
Lymphocyte Culture Test, Mixed | 3 | 0.0 |
Receptors, Interleukin-2/analysis | 4 | 1.0 |
Fluorescent Dyes | 2 | 0.0 |
T-Lymphocytes/*immunology | 13 | 0.0 |
Tumor Markers, Biological | 3 | 0.0 |
Actins/analysis | 3 | 1.0 |
Chronic Disease | 5 | 0.0 |
Cell Separation | 5 | 0.0 |
Aging/*immunology | 3 | 2.0 |
Frozen Sections | 2 | 2.0 |
Staining and Labeling | 2 | 0.0 |
Incidence | 2 | 0.0 |
Pregnancy | 6 | 0.0 |
Pregnancy Trimester, First | 3 | 1.0 |
T-Lymphocytes | 2 | 0.0 |
Intermediate Filaments/ultrastructure | 2 | 18.0 |
Macrophages/pathology | 2 | 1.0 |
Transglutaminases/analysis | 2 | 5.0 |
Immune Tolerance/immunology | 2 | 4.0 |
Immunoglobulins/blood | 2 | 2.0 |
B-Lymphocyte Subsets/*immunology | 3 | 3.0 |
Receptors, Antigen, T-Cell/analysis | 4 | 3.0 |
Lymphocytes/*pathology | 3 | 6.0 |
Antigens, CD57/immunology | 2 | 25.0 |
*Cell Differentiation | 2 | 0.0 |
Evaluation Studies | 2 | 0.0 |
Antibodies, Monoclonal | 7 | 0.0 |
Cell Division | 3 | 0.0 |
Fluorescent Antibody Technique | 6 | 0.0 |
Lymphocytes/*metabolism | 2 | 1.0 |
Phycoerythrin | 2 | 10.0 |
Desmin/analysis | 2 | 3.0 |
Skin Neoplasms/*pathology | 3 | 3.0 |
Hematopoietic Stem Cells/immunology | 2 | 2.0 |
*Killer Cells, Natural | 2 | 9.0 |
Base Sequence | 4 | 0.0 |
Ligands | 2 | 0.0 |
Molecular Sequence Data | 4 | 0.0 |
Sclerosis | 2 | 3.0 |
Antigens, CD8/analysis | 5 | 2.0 |
Antigens, Surface/*analysis | 2 | 1.0 |
Lymphocytes/immunology | 4 | 1.0 |
Killer Cells, Lymphokine-Activated/*immunology | 5 | 7.0 |
Species Specificity | 2 | 0.0 |
Flow Cytometry/*methods | 2 | 0.0 |
*Bone Marrow Transplantation | 3 | 0.0 |
T-Lymphocytes, Cytotoxic/*immunology | 2 | 0.0 |
Leukocytes, Mononuclear/*immunology | 2 | 1.0 |
Analysis of Variance | 2 | 0.0 |
Killer Cells, Natural | 3 | 7.0 |
Bone Marrow/*immunology | 2 | 3.0 |
Multiple Myeloma/*immunology | 3 | 8.0 |
Gene Expression | 3 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
T-Lymphocytes/*immunology/pathology | 2 | 3.0 |
Cytotoxicity, Immunologic/immunology | 2 | 2.0 |
HIV Infections/blood/*immunology | 2 | 3.0 |
HIV-1/immunology | 2 | 2.0 |
Immunologic Memory | 3 | 1.0 |
*Lymphocyte Subsets | 4 | 4.0 |
Gene Rearrangement, T-Lymphocyte/genetics | 3 | 16.0 |
Immunophenotyping/methods | 3 | 6.0 |
Cell Cycle/immunology | 2 | 6.0 |
Antibodies, Monoclonal/immunology | 3 | 0.0 |
Sex Factors | 2 | 0.0 |
Antigens, CD45/*analysis | 2 | 4.0 |
Cytokines/physiology | 2 | 1.0 |
Antigens, CD3/analysis | 4 | 1.0 |
Pilot Projects | 2 | 0.0 |
B-Lymphocytes/*immunology | 3 | 0.0 |
In Vitro | 4 | 0.0 |
Bronchoalveolar Lavage Fluid/*immunology | 2 | 6.0 |
Lymphocyte Subsets/*immunology | 8 | 6.0 |
Neutropenia/*immunology | 2 | 100.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
Antibodies, Monoclonal/diagnostic use | 4 | 0.0 |
HLA-DR Antigens/analysis | 4 | 0.0 |
Antigens, CD56 | 9 | 12.0 |
Cell Adhesion Molecules/*metabolism | 2 | 0.0 |
T-Lymphocyte Subsets/pathology | 2 | 7.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Connective Tissue/chemistry | 2 | 28.0 |
E-Selectin | 2 | 2.0 |
Genotype | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/metabolism | 2 | 1.0 |
Antigens, Neoplasm/analysis | 3 | 0.0 |
Intercellular Adhesion Molecule-1 | 2 | 0.0 |
Antigens, CD19 | 2 | 1.0 |
CD4-Positive T-Lymphocytes/classification | 2 | 50.0 |
T-Lymphocytes/metabolism | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/immunology | 2 | 1.0 |
Mice, Nude | 2 | 0.0 |
Antigens, CD/*blood | 2 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis | 2 | 2.0 |
Graves' Disease/immunology | 2 | 4.0 |
T-Lymphocytes, Suppressor-Effector/immunology | 2 | 1.0 |
Skin/immunology | 2 | 2.0 |
Herpesvirus 4, Human/immunology | 2 | 2.0 |
Herpesvirus 6, Human/immunology | 2 | 66.0 |
Antigens, CD45 | 2 | 0.0 |
Antigens, CD4/*analysis | 2 | 1.0 |
Killer Cells, Natural/*physiology | 2 | 4.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Leukocytes, Mononuclear/immunology | 2 | 0.0 |
Kinetics | 2 | 0.0 |
Antibodies, Monoclonal/*diagnostic use | 2 | 0.0 |
Histocompatibility Antigens Class I/immunology | 2 | 1.0 |
Antigens, CD3 | 3 | 0.0 |
Clone Cells | 4 | 0.0 |
Receptors, IgG | 3 | 2.0 |
Antigens, CD8 | 2 | 0.0 |
Receptors, Antigen, T-Cell/*analysis | 2 | 3.0 |
Receptors, Antigen, T-Cell, gamma-delta | 2 | 3.0 |
Antigens, Neoplasm/*analysis | 2 | 0.0 |
Lectins, C-Type/analysis | 2 | 33.0 |
Serine Endopeptidases/analysis | 2 | 5.0 |
Sensitivity and Specificity | 2 | 0.0 |
